Surgical treatment of age-related macular degeneration: Will there be a role in the future?

Clinical and Experimental Ophthalmology

Volumn 35, Issue 2, 2007, Pages 167-173

  Wong, David ^a   Durnian, Jon M ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

AMD; Maculatrans location; Surgery

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; STEROID;

ANGIOGENESIS; ARTICLE; BRUCH MEMBRANE; CELL TRANSPLANTATION; CHRONIC INFLAMMATION; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEMATOPOIETIC STEM CELL; HUMAN; HYPERTHERMIC THERAPY; LASER COAGULATION; OXIDATIVE STRESS; PATHOGENESIS; PATIENT SELECTION; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; RADIOTHERAPY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA TRANSLOCATION; RISK BENEFIT ANALYSIS; SUBRETINAL NEOVASCULARIZATION; SURGICAL RISK; VISUAL IMPAIRMENT; WOUND HEALING;

ANTIBODIES, MONOCLONAL; COST OF ILLNESS; HUMANS; MACULAR DEGENERATION; OPHTHALMOLOGIC SURGICAL PROCEDURES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33847789965     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2006.01410.x     Document Type: Article

References (73)

1. Evans JR, Fletcher AE, Wormald RP. Age-related macular degeneration causing visual impairment in people 75years or older in Britain: An add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community. Ophthalmology 2004; 111: 513-17.
2. Bruce I, McKennell A, Walker E. Blind and Partially Sighted Adults in Britain: The RNIB Survey, Vol. 1. London: HMSO, 1991.
3. Ellwein LB, Friedlin V, McBean AM, Lee PP. Use of eye care services among the 1991 Medicare population. Ophthalmology 1996; 103: 1732-43.
4. Evans J. Causes of Blindness and Partial Sight in England and Wales 1990-1991. London: HMSO, 1995.
5. Brown MM, Brown GC, Stein JD, Roth Z, Campenella J, Beauchamp GR. Age-related macular degeneration: Economic burden and value-based medicine analysis. Can J Ophthalmol 2005; 40: 277-87.
6. Bass EB, Marsh MJ, Mangione CM et al. Patients' perceptions of the value of current vision: Assessment of preference values among patients with subfoveal choroidal neovascularization -The Submacular Surgery Trials Vision Preference Value Scale: SST Report No. 6. Arch Ophthalmol 2004; 122: 1856-67.
7. National Statistics Online. Population by Age, UK. Office for National Statistics, UK. 2006. Available from: http://www.statistics.gov.uk/cci/ nugget.asp?id=949
8. Wright SE, Keeffe JE, Thies LS. Direct costs of blindness in Australia. Clin Experiment Ophthalmol 2000; 28: 140-2.
9. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin. One year results of 2 randomised clinical trial -TAP report 1. Arch Ophthalmol 1999; 117: 1329-45.
10. VIP Study Group. Verteporfin therapy of subfoveal choroidal neovascularisation in age-related macular degeneration: Two-year results of a randomised clinical trial including lesion with occult with no classical choroidal neovascularisation -verteporfin in photodynamic therapy report. Am J Ophthalmol 2001; 131: 541-60.
11. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol 1994; 112: 800-9.
12. Mauget-Faysse M, Chiquet C, Milea D et al. Long term results of radiotherapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 1999; 83: 923-8.
13. Reichel E, Berrocal AM, Ip M et al. Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology 1999; 106: 1908-14.
14. Sheraidah G, Steinmetz R, Maguire J et al. Correlation between lipids extracted from Bruch's membrane and age. Ophthalmology 1993; 100: 47-51.
15. Moore D, Clover G. The effect of age on the macromolecular permeability of human Bruch's membrane. Invest Ophthalmol Vis Sci 2001; 42: 2970-5.
16. Beatty S, Koh H, Henson D et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000; 45: 115-34.
17. Penfold P, Killingsworth M, Sarks S. Senile macular degeneration: The involvement of immunocompetent cells. Graefes Arch Clin Exp Ophthalmol 1985; 223: 69-76.
18. Guerne D, Tso M, Edward D et al. Antiretinal antibodies in serum of patients with age-related macular degeneration. Ophthalmology 1991; 98: 602-7.
19. Seddon J, Gensler G, Milton R et al. Association between C-reactive protein and age-related macular degeneration. JAMA 2004; 291: 704-10.
20. Seddon J, George S, Rosner B et al. Progression of age-related macular degeneration: Prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol 2005; 123: 774-82.
21. Young R. Pathophysiology of age related macular degeneration. Surv Ophthalmol 1987; 31: 291-306.
22. Goverdhan S, Lotery A. New insights into the molecular genetics of age related macular degeneration. Eye News 2005; 12 (2): 9-14.
23. Sheridan C, Rice D, Hiscott P, Wong D, Kent D. The presence of AC133 positive cells suggests a possible role of endothelial progenitor cells in the formation of choroidal neovascularization. Invest Ophthalmol Vis Sci 2006; 47: 1642-5.
24. Sahni J, Stanga P, Wong D, Harding S. Optical coherence tomography in photodynamic therapy for subfoveal choroidal neovascularisation secondary to age related macular degeneration: A cross sectional study. Br J Ophthalmol 2005; 89: 316-20.
25. Gass JD. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol 1994; 118: 285-98.
26. Thomas MA, Grand MG, Williams DF, Lee CM, Pesin SR, Lowe MA. Surgical management of subfoveal choroidal neovascularization. Ophthalmology 1992; 99: 952-68; discussion 975-6.
27. de Juan E Jr, Machemer R. Vitreous surgery for haemorrhagic and fibrous complications of age-related macular degeneration. Am J Ophthalmol 1988; 105: 25-9.
28. Blinder KJ, Peyman GA, Paris CL, Gremillion CM Jr. Submacular scar excision in age-related macular degeneration. Int Ophthalmol 1991; 15: 215-22.
29. Thomas MA, Kaplan HJ. Surgical removal of subfoveal neovascularisation in the presumed ocular histoplasmosis syndrome. Am J Ophthalmol 1991; 111: 1-7.
30. Thomas MA. The use of vitreoretinal surgical techniques in subfoveal choroidal neovascularisation. Curr Opin Ophthalmol 1992; 3: 349-56.
31. Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol 1994; 118: 559-68.
32. Ibanez HE, Williams DF, Thomas MA et al. Surgical management of submacular hemorrhage. A series of 47 consecutive cases. Arch Ophthalmol 1995; 113: 62-9.
33. Lim JI, Drews-Botsch C, Sternberg P Jr, Capone A Jr, Aaberg TM Sr. Submacular hemorrhage removal. Ophthalmology 1995; 102: 1393-9.
34. Moriarty AP, McAllister IL, Constable IJ. Initial clinical experience with tissue plasminogen activator (tPA) assisted removal of submacular haemorrhage. Eye 1995; 9 (Pt 5): 582-8.
35. Bressler NM, Bressler SB, Childs AL et al. Surgery for haemorrhagic neovascular lesion of age-related macular degeneration: Ophthalmic findings: SST report no. 13. Ophthalmology 2004; 111: 1993-2006.
36. Bressler NM, Bressler SB, Hawkins MJ, Sternberg P Jr, Thomas MA, Submacular Surgery Trials Pilot Study Investigators. Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. Ophthalmic outcomes submacular surgery trials pilot study report number 1. Am J Ophthalmol 2000; 130: 387-407.
37. Stanga PE, Kychenthal A, Fitzke FW et al. Retinal pigment epithelium translocation after choroidal neovascular membrane removal in age-related macular degeneration. Ophthalmology 2002; 109: 1492-8.
38. van Meurs JC, Van Den Biesen PR. Autologous retinal pigment epithelium and choroid translocation in patients with exudative age-related macular degeneration: Short-term follow-up. Am J Ophthalmol 2003; 136: 688-95.
39. Binder S, Krebs I, Hilgers RD et al. Outcome of transplantation of autologous retinal pigment epithelium in age-related macular degeneration: A prospective trial. Invest Ophthalmol Vis Sci 2004; 45: 4151-60.
40. Binder S, Stolba U, Krebs I et al. Transplantation of autologous retinal pigment epithelium in eyes with foveal neovascularization resulting from age-related macular degeneration: A pilot study. Am J Ophthalmol 2002; 133: 215-25.
41. Van Meurs JC, ter Averst E, Hofland LJ et al. Autologous peripheral retinal pigment epithelium transplantation in patients with subfoveal neovascular membranes. Br J Ophthalmol 2004; 88: 110-13.
42. Knoernschild T, Grasbon T, Wilsch C, Kampik A, Lutjen-Drecoll E. RPE cell transplants to non-immune-privileged sites of the eye transform into fibroblast-like cells. Curr Eye Res 2003; 27: 25-34.
43. Saigo Y, Abe T, Hojo M, Tomita H, Sugano E, Tamai M. Transplantation of transduced retinal pigment epithelium in rats. Invest Ophthalmol Vis Sci 2004; 45: 1996-2004.
44. Lindsey P, Finkelstein D, D'Anna S. Experimental retinal rotation. Invest Ophthalmol Vis Sci 1983; 24 (Suppl.): 242.
45. Machemer R, Steinhorst UH. Retinal separation, retinotomy and macular relocation. I. Experimental studies in the rabbit eye. Graefes Arch Clin Exp Ophthalmol 1993; 231: 629-34.
46. Machemer R, Steinhorst UH. Retinal separation, retinotomy and macular relocation: II. A surgical approach for age-related macular degeneration? Graefes Arch Clin Exp Ophthalmol 1993; 231: 635-41.
47. Pawlak D, Glacet-Bernard A, Papp M, Roquet W, Coscas G, Soubrane G. Limited macular translocation compared with photodynamic therapy in the management of subfoveal choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2004; 137: 880-7.
48. Chang AA, Tan W, Beaumont PE, Zeldovich A. Limited macular translocation for subfoveal choroidal neovascularization in age-related macular degeneration. Clin Experiment Ophthalmol 2003; 31: 103-9.
49. Fujii GY, de Juan E Jr, Pieramici DJ et al. Inferior limited macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: 1-year visual outcome and recurrence report. Am J Ophthalmol 2002; 134: 69-74.
50. Grossniklaus HE, Miskala PH, Green WR et al. Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: Submacular surgery trials report no. 7. Arch Ophthalmol 2005; 123: 914-21.
51. Wolf S, Lappas A, Weinberger AW, Kirchhof B. Macular translocation for surgical management of subfoveal choroidal neovascularizations in patients with AMD: First results. Graefes Arch Clin Exp Ophthalmol 1999; 237: 51-7.
52. Pertile G, Claes C. Macular translocation with 360 degree retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization. Am J Ophthalmol 2002; 134: 560-5.
53. Eckardt C, Eckardt U, Conrad HG. Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999; 237: 313-25.
54. Ohji M, Fujikado T, Kusaka S et al. Comparison of three technique of foveal translocation in patients with subfoveal choroidal neovascularization resulting from age-related macular degeneration. Am J Ophthalmol 2001; 132: 888-96.
55. Toth CA, Freedman SF. Macular translocation with 360-degree peripheral retinectomy: Impact of technique and surgical experience on visual outcomes. Retina 2001; 21: 293-303.
56. Aisenbrey S, Lafaut BA, Szurman P et al. Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol 2002; 120: 451-9.
57. Abdel-Meguid A, Lappas A, Hartmann K et al. One year follow up of macular translocation with 360 degree retinotomy in patients with age related macular degeneration. Br J Ophthalmol 2003; 87: 615-21.
58. Toth CA, Lapolice DJ, Banks AD, Stinnett SS. Improvement in near visual function after macular translocation surgery with 360-degree peripheral retinectomy. Graefes Arch Clin Exp Ophthalmol 2004; 242: 541-8.
59. Mruthyunjaya P, Stinnett SS, Toth CA. Change in visual function after macular translocation with 360 degrees retinectomy for neovascular age-related macular degeneration. Ophthalmology 2004; 111: 1715-24.
60. Wong D, Stanga P, Briggs M et al. Case selection in macular relocation surgery for age related macular degeneration. Br J Ophthalmol 2004; 88: 186-90.
61. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312: 1215-18.
62. Senn S. Dicing with Death: Chance, Risk and Health. Cambridge: Cambridge University Press, 2003.
63. Devereaux PJ, Beattie WS, Choi PT et al. How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ 2005; 331: 313-21.
64. Bartz-Schmidt KU, Aisenbrey S, Gelisken F. Full macular translocation versus PDT: 1 year results of a prospective, controlled, randomized pilot trial. Presented at the 3rd International Conference: Innovations in Vitreous and Retinal Diseases, Vienna, Austria, September 2005. Abstract. Available from: http://www.vienna-retina.at/abstracts.pdf
65. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001; 119: 198-207.
66. Barbazetto I, Burdan A, Bressler NM et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: Fluorescein angiographic guidelines for evaluation and treatment -TAP and VIP report No. 2. Arch Ophthalmol 2003; 121: 1253-68.
67. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16.
68. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North AM 2006; 19: 361-72.
69. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72 e5.
70. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-5.
71. Binder S, Krebs I, Abri A, Stolba U, Assadoulina A, Stanzel B. Autologous RPE-transplantation - suspension or flap? Presented at the 3rd International Conference: Innovations in Vitreous and Retinal Diseases, Vienna, Austria, September 2005. Abstract. Available from: http://www.vienna-retina.at/abstracts.pdf
72. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: The UK case. Br J Ophthalmol 2004; 88: 1107-12.
73. Boulton ME. [RPE transplantation: The challenges and the future]. Ophthalmologe 2004; 101: 877-81 (in German).